Syros Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Syros Pharmaceuticals
SYRS Stock  USD 0.27  0.02  8.00%   
Syros Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Syros Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Syros Pharmaceuticals financial statements helps investors assess Syros Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Syros Pharmaceuticals' valuation are summarized below:
Gross Profit
14.9 M
Market Capitalization
6.7 M
Enterprise Value Revenue
22.4955
Revenue
386 K
Earnings Share
(3.07)
There are over one hundred nineteen available fundamental trend indicators for Syros Pharmaceuticals, which can be analyzed over time and compared to other ratios. All traders should double-check Syros Pharmaceuticals' current fundamentals against the performance from 2010 to 2024 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 141.1 M in 2024. Enterprise Value is likely to drop to about 99.6 M in 2024

Syros Pharmaceuticals Total Revenue

7.61 Million

Check Syros Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Syros Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.1 M, Interest Expense of 5.4 M or Selling General Administrative of 18.9 M, as well as many indicators such as Price To Sales Ratio of 21.1, Dividend Yield of 0.0 or PTB Ratio of 13.91. Syros financial statements analysis is a perfect complement when working with Syros Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Syros Pharmaceuticals Correlation against competitors.
For more information on how to buy Syros Stock please use our How to Invest in Syros Pharmaceuticals guide.

Syros Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets147.5 M168.2 M115.6 M
Slightly volatile
Other Current Liabilities10.7 M13.8 M7.3 M
Slightly volatile
Total Current Liabilities22.2 M36.7 M15.3 M
Slightly volatile
Total Stockholder Equity15.8 M16.7 M65 M
Very volatile
Other Liabilities29.5 M28.1 M10 M
Slightly volatile
Property Plant And Equipment Net16.6 M19.5 M11.4 M
Slightly volatile
Accounts Payable12.1 M11.5 M4.1 M
Slightly volatile
Cash93.7 M139.5 M79.1 M
Slightly volatile
Non Current Assets Total21.7 M23.2 M14.8 M
Slightly volatile
Non Currrent Assets Other2.6 M3.7 M1.8 M
Slightly volatile
Other Assets5.4 M9.7 M4 M
Slightly volatile
Long Term Debt21.4 M34.6 M17.1 M
Slightly volatile
Cash And Short Term Investments119.8 M139.5 M96.7 M
Slightly volatile
Net Receivables1.4 M1.5 M5.1 M
Pretty Stable
Common Stock Total Equity28.2 K23 K18.7 K
Slightly volatile
Common Stock Shares Outstanding29.7 M28.3 M6.3 M
Slightly volatile
Liabilities And Stockholders Equity147.5 M168.2 M115.6 M
Slightly volatile
Non Current Liabilities Total120.6 M114.8 M36.1 M
Slightly volatile
Other Current Assets2.8 M5.5 M1.9 M
Slightly volatile
Other Stockholder Equity377.3 M739.4 M254.4 M
Slightly volatile
Total Liabilities159.1 M151.5 M52.4 M
Slightly volatile
Deferred Long Term Liabilities953.1 K1.5 M1.3 M
Very volatile
Property Plant And Equipment Gross19.9 M27.1 M13.7 M
Slightly volatile
Short and Long Term Debt8.1 M7.7 M3.4 M
Slightly volatile
Total Current Assets125.8 M145 M100.8 M
Slightly volatile
Short Term Debt11.9 M11.3 M2.5 M
Slightly volatile
Common Stock32.1 K26 K21.9 K
Slightly volatile
Property Plant Equipment12.6 M13.1 M8.8 M
Slightly volatile
Short and Long Term Debt Total34.7 M62.1 M21.3 M
Slightly volatile
Long Term Debt Total49.1 M46.7 M14.6 M
Slightly volatile
Capital Surpluse828.2 M788.7 M304 M
Slightly volatile
Current Deferred Revenue6.4 M5 M3.4 M
Slightly volatile
Capital Lease Obligations16.7 M20.9 M9.3 M
Slightly volatile
Net Invested Capital110.8 M57.9 M84.9 M
Slightly volatile
Net Working Capital122.2 M108.3 M88.4 M
Slightly volatile
Capital Stock32 K26 K36.3 K
Very volatile
Non Current Liabilities Other64.8 M61.7 M24.7 M
Slightly volatile

Syros Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization2.1 M2.3 M1.5 M
Slightly volatile
Selling General Administrative18.9 M28.3 M13.4 M
Slightly volatile
Other Operating Expenses87.4 M138.9 M62.4 M
Slightly volatile
Research Development68.1 M108.2 M48.8 M
Slightly volatile
Total Operating Expenses87.4 M138.9 M62.4 M
Slightly volatile
Preferred Stock And Other Adjustments2.9 M3.3 M3.6 M
Slightly volatile
Non Operating Income Net Other54.8 M52.2 M13.6 M
Slightly volatile
Reconciled Depreciation2.7 M2.3 M2 M
Slightly volatile
Interest Income7.2 M6.8 M1.4 M
Slightly volatile

Syros Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation7.3 M10.4 M5.5 M
Slightly volatile
Begin Period Cash Flow179.1 M170.6 M61.1 M
Slightly volatile
Depreciation1.9 M2.3 M1.5 M
Slightly volatile
Capital Expenditures258.4 K272 K1.9 M
Pretty Stable
End Period Cash Flow87.1 M141.6 M64.6 M
Slightly volatile
Issuance Of Capital Stock86.2 M43.3 M73.6 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio21.122.2079125
Slightly volatile
PTB Ratio13.9113.24324.6026
Slightly volatile
Days Sales Outstanding45.447.791.2 K
Pretty Stable
Book Value Per Share0.560.588246.9827
Slightly volatile
Stock Based Compensation To Revenue1.01.05016.0489
Slightly volatile
Capex To Depreciation0.110.12082.228
Slightly volatile
PB Ratio13.9113.24324.6026
Slightly volatile
Days Of Inventory On Hand1.0E-41.0E-41.0E-4
Slightly volatile
Payables Turnover0.290.19510.3236
Slightly volatile
Sales General And Administrative To Revenue2.72.846412.1793
Slightly volatile
Average Inventory0.550.5729 K
Pretty Stable
Research And Ddevelopement To Revenue10.3410.88547.4157
Slightly volatile
Capex To Revenue0.0260.02742.5194
Slightly volatile
Cash Per Share4.684.925850.6271
Slightly volatile
Days Payables Outstanding1.7 K1.9 K1.8 K
Slightly volatile
Income Quality0.690.66660.8398
Very volatile
Net Debt To EBITDA0.470.49270.9558
Pretty Stable
Current Ratio3.753.95258.0128
Pretty Stable
Tangible Book Value Per Share0.560.588246.9827
Slightly volatile
Receivables Turnover8.37.912.8138
Slightly volatile
Graham Number8.338.7691196
Slightly volatile
Shareholders Equity Per Share0.560.588246.8903
Slightly volatile
Debt To Equity2.742.61360.4448
Slightly volatile
Capex Per Share0.00910.00962.9573
Slightly volatile
Revenue Per Share0.330.35081.2252
Very volatile
Interest Debt Per Share2.261.71841.7126
Slightly volatile
Debt To Assets0.270.25890.0767
Slightly volatile
Operating Cycle33.2437.440.7221
Slightly volatile
Price Book Value Ratio13.9113.24324.6026
Slightly volatile
Days Of Payables Outstanding1.7 K1.9 K1.8 K
Slightly volatile
Ebt Per Ebit1.081.27590.9921
Very volatile
Company Equity Multiplier10.610.09332.6635
Slightly volatile
Long Term Debt To Capitalization0.710.67470.3527
Slightly volatile
Total Debt To Capitalization0.760.72330.1607
Slightly volatile
Debt Equity Ratio2.742.61360.4448
Slightly volatile
Quick Ratio3.753.95258.012
Pretty Stable
Net Income Per E B T1.00.60.9726
Slightly volatile
Cash Ratio3.613.80386.9571
Pretty Stable
Days Of Inventory Outstanding1.0E-41.0E-41.0E-4
Slightly volatile
Days Of Sales Outstanding45.447.791.2 K
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.161.00251.0746
Pretty Stable
Price To Book Ratio13.9113.24324.6026
Slightly volatile
Fixed Asset Turnover0.310.510.2752
Slightly volatile
Debt Ratio0.270.25890.0767
Slightly volatile
Price Sales Ratio21.122.2079125
Slightly volatile
Asset Turnover0.03340.05910.0297
Slightly volatile
Price Fair Value13.9113.24324.6026
Slightly volatile

Syros Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap141.1 M220.7 M142.8 M
Slightly volatile

Syros Fundamental Market Drivers

Cash And Short Term Investments139.5 M

Syros Upcoming Events

7th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
7th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Syros Pharmaceuticals Financial Statements

Syros Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Syros Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Syros Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Syros Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue5 M6.4 M
Total Revenue9.9 M7.6 M
Cost Of Revenue2.3 M2.1 M
Stock Based Compensation To Revenue 1.05  1.00 
Sales General And Administrative To Revenue 2.85  2.70 
Research And Ddevelopement To Revenue 10.88  10.34 
Capex To Revenue 0.03  0.03 
Revenue Per Share 0.35  0.33 
Ebit Per Revenue(12.98)(13.63)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Syros Stock Analysis

When running Syros Pharmaceuticals' price analysis, check to measure Syros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syros Pharmaceuticals is operating at the current time. Most of Syros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY